Humacyte

June is Men’s Health Month, an important time to focus on conditions that quietly impact long term health—starting with vascular disease.

Peripheral artery disease (PAD) affects millions of Americans and can quietly lead to serious outcomes like mobility loss, cardiovascular events, and even amputation. Each year, about 150,000 nontraumatic lower‑extremity amputations occur in the United States, with men representing the majority of patients.1,2
For men with advanced PAD, treatment can be especially challenging. Clinical studies show that 15–45% of patients with severe PAD or chronic limb threatening ischemia lack a suitable saphenous vein for use in bypassing the diseased artery, limiting traditional surgical options.3,4

Raising awareness of PAD and encouraging earlier conversations about vascular health can make a real difference—for long term limb and life outcomes. This Men’s Health Month, Humacyte encourages continued education, early PAD recognition, and informed conversations around vascular health—because circulation plays a critical role in long term limb and life outcomes.

Learn more about Humacyte and our groundbreaking science and vascular innovations at https://humacyte.com

References:
1. Creager MA, Matsush*ta K, Arya S, et al. Reducing nontraumatic lower extremity amputations by 20% by 2030: a policy statement from the American Heart Association. Circulation. 2021;143:e108‑e124.
2. Gill SS, Chaudhary M, Zakrison TL. Nontraumatic amputations in the United States—an urgent matter of equity. JAMA Surg. 2024;159(1):76‑77. doi:10.1001/jamasurg.2023.5523
3. Garbaisz D, Osztrogonácz P, Boros AM, Hidi L, Sótonyi P, Szeberin Z. Comparison of arterial and venous allograft bypass in chronic limb‑threatening ischemia. PLoS One. 2022;17(10):e0275628. doi:10.1371/journal.pone.0275628
4. Taylor LM Jr, Edwards JM, Brant B, Phinney ES, Porter JM. Autogenous reversed vein bypass for lower extremity ischemia in patients with absent or inadequate greater saphenous vein. Am J Surg. 1987;153(5):505‑510. doi:10.1016/0002‑9610(87)90803‑8

Humacyte is a trademark and property of Humacyte Global, Inc. © 2026 Humacyte Global Inc. All Rights Reserved.

Join Us Tonight to Learn More !

There are clear unmet needs in AV Access for Women. (1,2)

Join leaders in vascular innovation at the Women in Vascular Surgery Forum, sponsored by Humacyte. The team will share recent Interim Results from the Women-Only Study in AV Access.

Thursday, June 11, 2026
7:00–8:30 PM EST
Sheraton, 2nd Floor, Back Bay C

Speakers:
Young Erben, MD, FACS
Associate Professor of Surgery
Mayo Clinic in Jacksonville, FL

Laura Niklason, MD, PhD
Founder, President & CEO
Humacyte Global, Inc.

Be part of the conversation advancing care for women.

ALSO VISIT our MEDICAL INFORMATION TEAM at SVS - BOOTH #307

Learn more about Humacyte here: https://humacyte.com

For uses other than the FDA approval in the extremity vascular injury indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Sources: 1. USRDS 2025 Annual Data. 2. Coker et al., The Journal of Vascular Access, 2018.

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global, Inc. All Rights Reserved.

$HUMA

There are clear unmet needs in AV Access for Women. (1,2)

Join leaders in vascular innovation at the Women in Vascular Surgery Forum, sponsored by Humacyte. The team will share recent Interim Results from the Women-Only Study in AV Access.

Thursday, June 11, 2026
7:00–8:30 PM EST
Sheraton, 2nd Floor, Back Bay C

Speakers:
Young Erben, MD, FACS
Associate Professor of Surgery
Mayo Clinic in Jacksonville, FL

Laura Niklason, MD, PhD
Founder, President & CEO
Humacyte Global, Inc.

Be part of the conversation advancing care for women.

ALSO VISIT our MEDICAL INFORMATION TEAM at SVS - BOOTH #307

Learn more about Humacyte here: https://humacyte.com

For uses other than the FDA approval in the extremity vascular injury indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Sources: 1. USRDS 2025 Annual Data. 2. Coker et al., The Journal of Vascular Access, 2018.

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global, Inc. All Rights Reserved.

$HUMA

Women with AV Access face clear unmet needs.
• 50% fail AVF maturation (vs. 37% in men)1
• 30% use catheter for hemodialysis (vs. 24% in men)1
• 2× higher risk of catheter dysfunction2
• 1 in 2 use infection-prone access – catheters and synthetic grafts1

Be part of the conversation advancing care for women.
VISIT our MEDICAL INFORMATION TEAM at SVS - BOOTH #307

Learn more about Humacyte here: www.humacyte.com

For uses other than the FDA approval in the extremity vascular injury indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

REFERENCES: 1. USRDS 2025 Annual Data. 2. Coker et al., The Journal of Vascular Access, 2018.

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global, Inc. All Rights Reserved.

$HUMA

We’re excited to be at VAM 2026 and proud to host a Hands on/SIM Lab featuring Symvess® acellular tissue engineered vessel-tyod.

During the VAM 2026 Hands on/SIM Lab, participants can practice handling and implantation techniques, perform anastomosis, and apply proper clamping and procedural methods—all supported by the Humacyte team throughout the session.

SIM Lab Location: Hynes Convention Center, Second Level, Auditorium
• Thursday, June 11: 10:15 AM – 6:15 PM
• Friday, June 12: 9:30 AM – 2:00 PM

Be sure to also stop by Booth 307 to connect with the Humacyte team and continue the conversation.

Contact Us Here: https://symvess.com/contact-us/

Learn more about Symvess here: https://bit.ly/atev_prod_huma
PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://bit.ly/4dl5tuL

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

BOXED WARNING: GRAFT FAILURE: Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

Trademarks are property of Humacyte Global, Inc
Other trademarks are property of their respective owners.
© 2026 Humacyte Global, Inc. All Rights Reserved. US-SYM-000348

$HUMA